Beyond Air (XAIR) Stock Price, News & Analysis

Company Overview

Beyond Air, Inc. (NASDAQ: XAIR) is a clinical-stage medical device company focused on the development and commercialization of proprietary, gas-enabled therapeutics for hospital and outpatient settings. The company’s core technology delivers inhaled nitric oxide (iNO) on demand to target and treat diseases of the respiratory tract, leveraging the antimicrobial, anti-inflammatory and vasodilatory properties of gas-formulated nitric oxide. Beyond Air is advancing these therapies to address serious pulmonary conditions with significant unmet medical need.

The company’s lead platform, LungFit™ PH, is designed to provide optimized gas delivery for patients with pulmonary hypertension and other vascular lung disorders. LungFit devices generate and dispense pure nitric oxide at precise concentrations, enabling continuous outpatient treatment without reliance on compressed gas cylinders. Beyond Air is also pursuing applications of iNO in bronchiectasis, cystic fibrosis and in clearing drug-resistant pulmonary infections. Ongoing clinical trials and regulatory submissions aim to expand approved indications in the United States and Europe.

Founded in 2004 and headquartered in Brooklyn, New York, Beyond Air has its U.S. manufacturing and research operations in Massachusetts. The company’s management has steered a series of strategic partnerships and academic collaborations to advance clinical programs, including work with major medical centers in North America and the European Union. Beyond Air completed its initial public offering in 2021, positioning the organization to accelerate commercialization efforts and scale its product pipeline.

Under the leadership of Chief Executive Officer Eric A. Dyer, Beyond Air’s executive team combines expertise in medical devices, pharmaceutical development and regulatory affairs. The company remains committed to expanding access to inhaled nitric oxide therapy through ongoing research, manufacturing scale-up and health-economic studies. Beyond Air continues to explore new indications and delivery platforms to broaden the impact of its proprietary gas technology on respiratory health worldwide.

Key Stats

• Today's Range: $2.90 to $3.70
• 50-Day Range: $0.16 to $3.05
• 52-Week Range: $2.90 to $13.52
• Volume: 277,812 shs
• Average Volume: 79,327 shs
• Market Capitalization: $263.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.50
• Consensus Rating: Buy

Beyond Air Stock Analysis - MarketRank™

Beyond Air scored higher than 69% of companies evaluated by MarketBeat, and ranked 322nd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Buy

Consensus Rating

Beyond Air has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Beyond Air has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Beyond Air are expected to grow in the coming year, from ($0.79) to ($0.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Beyond Air is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Beyond Air is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Beyond Air has a P/B Ratio of 17.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.68% of the float of Beyond Air has been sold short.

Short Interest Ratio / Days to Cover

Beyond Air has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Beyond Air has recently decreased by 98.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beyond Air does not currently pay a dividend.

Dividend Growth

Beyond Air does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -0.91

Percentage of Shares Shorted

0.68% of the float of Beyond Air has been sold short.

Short Interest Ratio / Days to Cover

Beyond Air has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Beyond Air has recently decreased by 98.39%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.64

News Sentiment

Beyond Air has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Beyond Air this week, compared to 2 articles on an average week.

Search Interest

16 people have searched for XAIR on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

8 people have added Beyond Air to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Beyond Air insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.40% of the stock of Beyond Air is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 31.50% of the stock of Beyond Air is held by institutions.

XAIR Stock Analysis - Frequently Asked Questions

How have XAIR shares performed this year?

Beyond Air's stock was trading at $0.3585 at the start of the year. Since then, XAIR stock has increased by 750.8% and is now trading at $3.05.

How were Beyond Air's earnings last quarter?

Beyond Air, Inc. (NASDAQ:XAIR) released its quarterly earnings data on Tuesday, June, 17th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. The company earned $1.15 million during the quarter, compared to the consensus estimate of $1.39 million. Beyond Air had a negative trailing twelve-month return on equity of 233.96% and a negative net margin of 1,258.46%.
Read the conference call transcript.

When did Beyond Air's stock split?

Beyond Air shares reverse split on the morning of Monday, July 14th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, July 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Beyond Air?

Shares of XAIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Beyond Air own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Beyond Air investors own include Pfizer (PFE), NVIDIA (NVDA), General Motors (GM), Meta Platforms (META), Corbus Pharmaceuticals (CRBP), Norwegian Cruise Line (NCLH) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 6/17/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:XAIR
• CIK: 1641631
• Web: www.beyondair.net
• Phone: (516) 665-8200
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Beyond Air: $1.50
• High Price Target: $2.00
• Low Price Target: $1.00
• Potential Upside/Downside: -50.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.62 million
• Net Margins: -1,258.46%
• Pretax Margin: -1,308.47%
• Return on Equity: -233.96%
• Return on Assets: -113.92%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 3.20
• Quick Ratio: 2.72

Sales & Book Value

• Annual Sales: $3.70 million
• Price / Sales: 71.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.17 per share
• Price / Book: 17.94

Miscellaneous

• Outstanding Shares: 86,370,000
• Free Float: 69,614,000
• Market Cap: $263.43 million
• Optionable: Optionable
• Beta: 0.22